INTRODUCTION
Cardiovascular disease (CVD) and type 2 diabetes mellitus (T2DM) have reached epidemic proportions worldwide, becoming increasingly pressing public health problems. The prevalence of T2DM ranges from 6.9% to 10 .2% in developed countries, and exceeds 7% in developing countries [1, 2] . CVD accounts for 17.5 million deaths annually, an estimated 31% of all deaths worldwide [3] .
A growing body of evidence suggests strong links between T2DM, CVD and hypertension [high blood pressure (BP)]. Firstly, T2DM is known to be a major risk factor for cardiovascular (CV) morbidity and mortality [4] . In addition to microvascular complications (nephropathy, retinopathy and neuropathy), T2DM is associated with macrovascular complications including CVD, cerebrovascular disease and peripheral artery disease. Secondly, the majority of patients with T2DM are overweight or obese, a further risk factor for both CVD and hypertension [5] .
Finally, hypertension is a common co-morbidity in both CVD and T2DM. A substantial proportion of people with T2DM
have concomitant hypertension (20-60%, depending on age, sex, ethnicity and body mass index). Hypertension almost doubles the risk of all-cause mortality, and increases the risk of coronary artery disease threefold [6, 7] . In addition, hypertension enhances the progression of diabetic complications such as nephropathy, retinopathy and neuropathy.
Lowering of BP, using appropriate antihypertensive treatment, reduces the risk of complications in T2DM patients [8] [9] [10] . The 8th Joint National Committee (JNC)
recommendations for the management of hypertension in adults suggest targets of \140 mmHg for systolic BP (SBP) and \85-90 mmHg for diastolic BP (DBP) in patients with T2DM [11] . However, hypertension associated with T2DM is especially challenging to treat [12] , with most T2DM patients needing more than one drug for BP control. A systematic survey of general practitioners in Canada revealed that 28-39% of hypertensive patients with underlying T2DM failed to achieve the BP targets recommended by the current JNC guidelines [13, 14] . New and improved treatment options for BP lowering are urgently needed to improve CV prognosis among patients with T2DM and hypertension. Sodium-glucose cotransporter 2 (SGLT2)
inhibitors are a novel class of drugs that have been extensively investigated for the treatment of hyperglycemia in T2DM. These drugs reduce hyperglycemia by blocking renal glucose reabsorption, thereby promoting increased renal excretion of glucose [15] . Over and above glycemic control, these drugs have shown benefit with respect to a number of CV risk factors [16, 17] . The present review discusses the potential role of SGLT2 inhibitors in addressing risk factors and complications associated with T2DM, such as hypertension, from a cardiology perspective. It also discusses the potential use of SGLT2 in acute and chronic CV syndromes and obesity.
This article is based on previously conducted studies and does not involve any new studies of human or animal subjects performed by any of the authors. However, these are not clinically significant, and rarely lead to discontinuation of therapy.
SGLT2 INHIBITORS

EFFECTS ON HEMODYNAMICS
The favorable effects of SGLT2 inhibitors on a number of conventional CV risk factors, such as BP, blood glucose levels and body weight, are well documented (Fig. 1 
Effect on Pulse
There is no increase in pulse rate with SGLT2 inhibitors. A 104-week outcome study of canagliflozin indicated that the 100 and 300 mg dose reduced SBP and DBP compared with glimepiride, with no notable changes in pulse rate [31] . This contrasts with the tachycardic reported with use of other glucose lowering drugs such as glucagon like peptide 1 receptor agonists.
In the short term, these BP-lowering effects have been attributed to both preload and afterload reduction. This is a unique feature of SGLT2 inhibitors, which needs to be highlighted in cardiology circles. Long-term effects may be mediated through RAAS activation and/or reductions in body weight [26] .
EFFECTS ON BODY WEIGHT
Reductions in body weight are consistently observed with SGLT2 inhibitor treatment (Fig. 1) . This effect may be attributed to diuresis or volume depletion, as well as to net loss of calories in the form of glucose. Among hypothesis that patients with T2DM, who were on long term dapaglifolzin, will have a reduced incidence of the composite endpoint of CV death, myocardial infarction or ischemic stroke. This study will also seek to exclude the unacceptable CV risk from the drug in these patients. The teams have plans to enroll over 17,000 participants with T2DM and have indicated a target of 1390 3-point MACE. The results are expected to be out in 2018, with a hope to see if dapagliflozin could offer CV benefits as well as addressing safety related issues.
EFFECTS ON LIPID PROFILES
In a recently published study of the EMPA-REG OUTCOME trial (ClinicalTrials.gov identifier: NCT01131676), it was found that in patients with T2DM who were at high CV risk, empagliflozin was effective in slowing the progression of kidney disease. With an aim to assess the long term renal effects of empagliflozin, a secondary analysis of the pre-specified component of the secondary microvascular outcome of the trial was performed. The study reported a lower incidence or worsening nephropathy in the Empagliflozin arm (12.7%) when compared with the placebo (18.8%). There were raised serum creatinine levels in 1.5% of patients in the empagliflozin group versus 2.6% in the placebo group, which was a significant reduction of the relative risk. The need for renal replacement therapy was lower in the empagliflozin group than the placebo. The study concluded that the use of empagliflozin in patients with T2DM at high CV risk was associated with slower progression of kidney disease compared with the placebo [37] .
CONCLUSION
The safety and efficacy of SGLT2 inhibitors 
